GlassScriptPhysician profile
Serina Schama
NPI 1457010175
$4,851.95
in general payments reported to CMS, 2019-2025
14 companies · $3,458 in 2025
The $3,458 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,394 · 2025: $3,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,692 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,691.62 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $877.80 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $747.53 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $600.38 | 2024-2025 | Abilify Maintena, Rexulti |
| Abbvie INC. | $592.08 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $356.58 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $352.70 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $293.53 | 2024-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $272.66 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $193.11 | 2025 | Cobenfy |
| Indivior INC. | $189.18 | 2024-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $134.31 | 2024-2025 | Qelbree |
| Alkermes, INC. | $121.81 | 2024-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $76.74 | 2024-2025 | Xelstrym, Secuado |
| Luye Pharma (USA) LTD. | $43.54 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serina Schama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.